LINK PHARMA CHEM LTD.

Link Pharma Chem Ltd has announced that its Board of Directors will convene on November 3, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. The company also confirmed the closure of its trading window from October 1, 2026, which will reopen 48 hours after the declaration of these financial results.

Link Pharma Chem Ltd has received an order from the GST Appellate Authority, Tribunal, Vadodara, significantly reducing its final demand for GST and penalty for FY 2021-22. The original demand of ₹1,32,94,322 has been reduced to ₹16,29,852, and the penalty has been reduced from ₹13,29,433 to ₹2,05,605. The company cited mismatches in tax liability declarations and excess ITC availed as reasons for the initial demand. While the financial impact is limited to the reduced demand and penalty, the company intends to file an appeal with the appropriate authority. There is no material impact on the company's operations.

Link Pharma Chem Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ending September 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The specific date for the Board Meeting to consider these financial results will be communicated separately. This measure is standard practice to prevent insider trading during periods when material non-public information may be under consideration.

Link Pharma Chem Ltd has announced the re-appointment of Mr. Rishikesh Thakur as Managing Director for a term of three years, effective September 24, 2026. This decision was ratified through a resolution passed at the company's Annual General Meeting held on August 20, 2026. Mr. Thakur, who holds a B.Eng. in Polymer from London Metropolitan University, brings over 15 years of experience in the chemical industry, encompassing manufacturing, R&D, project management, and business development. He is the son of Mr. Satish G. Thakur, the Chairman & Whole-time Director of the company.

Link Pharma Chem Ltd announced the re-appointment of Mr. Satish G. Thakur as Chairman and Whole-time Director for a term of three years, effective June 24, 2026. This decision was ratified at the company's Annual General Meeting held on August 20, 2026. Mr. Thakur, associated with the company since its incorporation, brings over 43 years of industry experience, including expertise in project design and development. He is also the father of the current Managing Director, Mr. Rishikesh Thakur.

Link Pharma Chem Ltd held its 41st Annual General Meeting (AGM) on August 20, 2026, via Video Conferencing. All six resolutions presented to the shareholders were passed with the requisite majority. The resolutions included the adoption of audited financial statements for FY26, re-appointment of a director retiring by rotation, and ratification of cost auditor remuneration. The meeting saw participation through e-voting and poll, with a total of 2,618,698 votes polled out of 4,440,568 shares outstanding, representing 58.97% of the total shares. The voting results indicate strong shareholder approval for all agenda items.

Link Pharma Chem Limited announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results along with the Limited Review Report. The meeting commenced at 12:15 p.m. and concluded at 02:00 p.m. The company's registered office is located in Vadodara, Gujarat. CNK & Associates LLP, Chartered Accountants, provided the Independent Auditor's Review Report.

Link Pharma Chem Ltd announced the outcome of its Board Meeting held on August 5, 2026. The board considered and approved the unaudited financial results for the quarter ended June 30, 2026, along with the limited review report. The meeting commenced at 12:15 p.m. and concluded at 02:00 p.m. The company also disclosed changes in Directors and Key Managerial Personnel as per SEBI regulations. CNK & Associates LLP provided the independent auditor's review report.

Link Pharma Chem Ltd has informed the stock exchanges about the dispatch of letters containing the web link to its Annual Report for the Financial Year 2025-2026. This action is in compliance with Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015, and is directed towards shareholders who have not registered their email addresses. The company also provided the direct web link and the exact path to access the full report online. Additionally, the communication serves as a reminder for shareholders to update their KYC details and dematerialize physical securities as per recent SEBI mandates, highlighting the implications for payments like dividends if KYC is not updated.

Link Pharma Chem Ltd has announced that its Board of Directors will convene on August 5, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026. Concurrently, the company has confirmed the closure of its trading window from July 1, 2026, which will reopen 48 hours after the declaration of these financial results, in compliance with SEBI regulations.